List of Excipients in API olmesartan medoxomil and hydrochlorothiazide 20/12.5
✉ Email this page to a colleague
Excipients in ANDA-approved (generic) drugs containing olmesartan medoxomil and hydrochlorothiazide 20/12.5
Detailed excipient profiles for olmesartan medoxomil and hydrochlorothiazide 20/12.5
Excipient focus: CELLULOSE, MICROCRYSTALLINE
olmesartan medoxomil and hydrochlorothiazide 20/12.5 drug variants containing CELLULOSE, MICROCRYSTALLINE
olmesartan medoxomil and hydrochlorothiazide 20/12.5 drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
olmesartan medoxomil and hydrochlorothiazide 20/12.5 drug variants containing FERRIC OXIDE RED
olmesartan medoxomil and hydrochlorothiazide 20/12.5 drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
olmesartan medoxomil and hydrochlorothiazide 20/12.5 drug variants containing FERRIC OXIDE YELLOW
olmesartan medoxomil and hydrochlorothiazide 20/12.5 drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE
olmesartan medoxomil and hydrochlorothiazide 20/12.5 drug variants containing HYDROXYPROPYL CELLULOSE
olmesartan medoxomil and hydrochlorothiazide 20/12.5 drug variants not containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED
olmesartan medoxomil and hydrochlorothiazide 20/12.5 drug variants containing HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED
| Company | Ingredient | NDC |
|---|---|---|
| Torrent Pharmaceuticals Limited | olmesartan medoxomil and hydrochlorothiazide 20/12.5 | 13668-251 |
| REMEDYREPACK INC | olmesartan medoxomil and hydrochlorothiazide 20/12.5 | 70518-1344 |
| >Company | >Ingredient | >NDC |
olmesartan medoxomil and hydrochlorothiazide 20/12.5 drug variants not containing HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED
| Company | Ingredient | NDC |
|---|---|---|
| A-S Medication Solutions | olmesartan medoxomil and hydrochlorothiazide 20/12.5 | 50090-5694 |
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
olmesartan medoxomil and hydrochlorothiazide 20/12.5 drug variants containing LACTOSE MONOHYDRATE
olmesartan medoxomil and hydrochlorothiazide 20/12.5 drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
olmesartan medoxomil and hydrochlorothiazide 20/12.5 drug variants containing LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| A-S Medication Solutions | olmesartan medoxomil and hydrochlorothiazide 20/12.5 | 50090-5694 |
| >Company | >Ingredient | >NDC |
olmesartan medoxomil and hydrochlorothiazide 20/12.5 drug variants not containing LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Torrent Pharmaceuticals Limited | olmesartan medoxomil and hydrochlorothiazide 20/12.5 | 13668-251 |
| REMEDYREPACK INC | olmesartan medoxomil and hydrochlorothiazide 20/12.5 | 70518-1344 |
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
olmesartan medoxomil and hydrochlorothiazide 20/12.5 drug variants containing MAGNESIUM STEARATE
olmesartan medoxomil and hydrochlorothiazide 20/12.5 drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
olmesartan medoxomil and hydrochlorothiazide 20/12.5 drug variants containing TALC
olmesartan medoxomil and hydrochlorothiazide 20/12.5 drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
olmesartan medoxomil and hydrochlorothiazide 20/12.5 drug variants containing TITANIUM DIOXIDE
olmesartan medoxomil and hydrochlorothiazide 20/12.5 drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
